RHEI Pharma to Market Oral Mucositis Treatment in China
September 30, 2010 at 11:26 AM EDT
RHEI Pharma has fleshed out its China marketing agreement with Access Pharmaceuticals for MuGard™, the latter company’s novel treatment for oral mucositis, a side effect of cancer treatment. MuGard is a ready-to-use mucoadhesive oral wound rinse and coating. RHEI specializes in bringing Western drugs to China. The original agreement between the two entities was signed almost three years ago. More details.... Stock Symbol: (OTCBB: ACCP)